{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:27:28Z","timestamp":1793237248330,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pressurized metered dose inhalers (pMDI) are a vital therapy for the treatment of lung diseases such as asthma and chronic obstructive pulmonary disease (COPD). In pMDI, the propellants used to deliver the drug to the lungs are hydrofluorocarbons (HFC). However, the current HFCs in use have large global warming potential (GWP). In order to reduce or eliminate the use of propellants with large global warming potential, efforts are underway within the pharmaceutical industry to transition to the use of low GWP propellants in pMDI, while maintaining their effectiveness in treating disease. The current switch from higher GWP propellants mirrors the switch from chlorofluorocarbon (CFC) propellants to HFCs undertaken in the 1990\u2019s, which was driven by ozone depletion concerns. In this paper, the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS) discusses aspects of the switch to low GWP propellants from the perspective of materials compatibility of pMDI components with low GWP propellants. Leveraging the learnings and advances in pMDI component materials implemented following the switch from CFCs, industry is well positioned to make the change. This paper describes the utility of the low GWP propellants being developed for use in pMDI and the learnings from the previous transition that are being leveraged by industry. The current state of development will be described, including a review of available literature supporting the transition to low GWP propellants.<\/jats:p>","DOI":"10.1208\/s12249-025-03060-4","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T16:31:21Z","timestamp":1739896281000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Materials Compatibility Considerations for the Transition to Low Global Warming Potential Propellants for Pressurized Metered Dose Inhalers"],"prefix":"10.1208","volume":"26","author":[{"given":"Dan","family":"Dohmeier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atish","family":"Sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Cavecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Matos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Lostritto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7630-3929","authenticated-orcid":false,"given":"Lee","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"key":"3060_CR1","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1208\/s12249-013-0063-x","volume":"15","author":"PB Myrdal","year":"2014","unstructured":"Myrdal PB, Sheth P, Stein SW. Advances in metered dose inhaler technology: formulation development. AAPS PharmSciTech. 2014;15:434\u201355. https:\/\/doi.org\/10.1208\/s12249-013-0063-x.","journal-title":"AAPS PharmSciTech"},{"key":"3060_CR2","first-page":"1201","volume":"50","author":"CL Leach","year":"2005","unstructured":"Leach CL. The CFC to HFA transition and its impact on pulmonary drug development. Respir Care. 2005;50:1201\u20136.","journal-title":"Respir Care"},{"key":"3060_CR3","unstructured":"IPCC, 2007: Climate Change 2007: Synthesis Report. Contribution of Working Groups I, II and III to the Fourth Assessment Report of the Intergovernmental Panel on Climate Change\u00a0[Core Writing Team, Pachauri, R.K and Reisinger, A. (eds.)]. IPCC, Geneva, Switzerland, 104 pp. Table TS.2 in the Technical Summary. Available from https:\/\/www.ipcc.ch\/. Accessed 10 Feb 2025."},{"key":"3060_CR4","unstructured":"Text of Kigali Amendment including corrections. In: UN Environment Programme, Ozone Secretariat. https:\/\/ozone.unep.org\/treaties\/montreal-protocol. Accessed 29 Mar 2024."},{"key":"3060_CR5","unstructured":"European Medicines Agency. Questions and answers on data requirements when transitioning low global warming potential (LGWP) propellants in oral pressurised metered dose inhalers. https:\/\/www.ema.europa.eu\/en. Accessed 09 May 2024."},{"key":"3060_CR6","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1208\/s12249-013-0062-y","volume":"15","author":"SW Stein","year":"2014","unstructured":"Stein SW, Sheth P, Hodson PD, Myrdal PB. Advances in metered dose inhaler technology: hardware development. AAPS PharmSciTech. 2014;15:326\u201338. https:\/\/doi.org\/10.1208\/s12249-013-0062-y.","journal-title":"AAPS PharmSciTech."},{"key":"3060_CR7","unstructured":"Product Quality Research Institute. 2006. https:\/\/pqri.org\/wp-content\/uploads\/2015\/08\/pdf\/LE_Recommendations_to_FDA_09-29-06.pdf. Accessed July 5, 2024."},{"key":"3060_CR8","doi-asserted-by":"publisher","unstructured":"Leachables and Extractables Handbook: Safety Evaluation, Qualification, and Best Practices Applied to Inhalation Drug Products. Ball DJ, Norwood DL, Stults CLM, Nagao LM, eds. First published:13 January 2012. Print ISBN:9780470173657, Online ISBN:9781118147672. https:\/\/doi.org\/10.1002\/9781118147672. 2012 John Wiley & Sons, Inc. Hoboken, NJ.","DOI":"10.1002\/9781118147672."},{"key":"3060_CR9","unstructured":"International Pharmaceutical Aerosol Consortium on Regulation and Science. Recommended Baseline Requirements for Materials used in Orally Inhaled and Nasal Drug Products (OINDP). https:\/\/www.ipacrs.org\/_files\/ugd\/932589_4ddd4088c47d472c866194b64ddafa82.pdf. Accessed July 5, 2024."},{"key":"3060_CR10","unstructured":"Extractables and Leachables Safety Information Exchange (ELSIE). Concepts in Leachables Risk Management. Screening and Materials Selection. https:\/\/www.elsiedata.org\/material-screening. Accessed on July 5, 2024."},{"key":"3060_CR11","unstructured":"IPAC-RS Workshop: Transition to LGWP Propellants for MDIs, https:\/\/www.ipacrs.org\/ipac-rsworkshoptransitiontolgwp. Accessed August14, 2024."},{"key":"3060_CR12","unstructured":"Honeywell, \u201cSolstice\u00ae Propellant\u201d Technical Bulletin, 2041 FP SOLA4 | December 2017. https:\/\/advancedmaterials.honeywell.com\/us\/en\/products\/propellant-and-solvents\/industrial-propellant\/solstice-propellant#resources. Accessed on 17 September 2024."},{"key":"3060_CR13","unstructured":"Koura, \u201cZephex\u00ae HFA 134a Medical Propellant\u201d. https:\/\/www.kouraglobal.com\/applications\/medical-propellants\/zephex-134a\/. Accessed on 17 September 2024."},{"key":"3060_CR14","unstructured":"Daikin, \u201cSOLKANE\u2122 227 pharma \u2013 HFA Propellant for Medical Use, 2023\u201d. https:\/\/www.daikinchem.de\/products-and-performance\/pharma-propellants. Accessed on 17 September 2024."},{"key":"3060_CR15","unstructured":"Koura, \u201cZephex\u00ae 152a Physical Properties\u201d. https:\/\/www.kouraglobal.com\/applications\/medical-propellants\/zephex-152a\/. Accessed on 17 September 2024."},{"key":"3060_CR16","unstructured":"Dupont, \u201cDupont\u2122 FM-200 (HFC 227ea) Fire Extinguishing Agent\u201d. https:\/\/www.firesecurity.gr\/Pdf\/k23261_FM-200_PUSH.pdf. Accessed on 17 September 2024."},{"key":"3060_CR17","unstructured":"Honeywell, \u201cSolstice\u00ae ZE Refrigerant (HFO-1234ZE)\u201d Brochure, BRO-22\u201340-EN | 07\/22. https:\/\/advancedmaterials.honeywell.com\/us\/en\/products\/air-conditioning-refrigeration-and-heating\/solstice-hfos\/solstice-ze-r-1234ze#resources. Accessed on 17 September 2024."},{"key":"3060_CR18","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1252\/jcej.13we021","volume":"46","author":"K Tanaka","year":"2013","unstructured":"Tanaka K, Higashi Y. Surface Tension of trans-1,3,3,3 tetrafluoropropene and trans1,3,3,3-tetrafluopropene + Difluoromethane mixtures. J Chem Eng Jpn. 2013;46:371\u20135.","journal-title":"J Chem Eng Jpn"},{"issue":"8","key":"3060_CR19","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1080\/10408444.2018.1504276","volume":"48","author":"GM Rusch","year":"2018","unstructured":"Rusch GM. The development of environmentally acceptable fluorocarbons. Crit Rev Toxicol. 2018;48(8):615\u201365.","journal-title":"Crit Rev Toxicol"},{"key":"3060_CR20","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ijpharm.2014.01.039","volume":"465","author":"JW Ivey","year":"2014","unstructured":"Ivey JW, Lewis D, Church T, Finlay WH, Vehring R. A correlation equation for the mass median aerodynamic diameter of the aerosol emitted by solution metered dose inhalers. Int J Pharm. 2014;465:18\u201324.","journal-title":"Int J Pharm"},{"key":"3060_CR21","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1080\/02786826.2018.1433814","volume":"52","author":"B Gavtash","year":"2018","unstructured":"Gavtash B, Versteeg HK, Hargrave G, Myatt B, Lewis D, Church T, Brambilla G. Aerosol Sci Technol. 2018;52:494\u2013504. https:\/\/doi.org\/10.1080\/02786826.2018.1433814.","journal-title":"Aerosol Sci Technol"},{"key":"3060_CR22","unstructured":"Kuehl PJ, Corr S, Leach C. Safety, tolerance and pharmacokinetics of HFA-152a in healthy volunteers. Respir Drug Del 2022;1\u20139."},{"key":"3060_CR23","unstructured":"Study Details | A Study to Compare the Effects of Two Propellants in Adults With Mild Asthma | ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05472662. Accessed August 15, 2024."},{"key":"3060_CR24","unstructured":"Study Details | Comparison Between CHF5993 pMDI 200\/6\/12,5mg HFA-152a VS CHF5993 pMDI 200\/6\/12,5mg HFA-134a in Subjects With Asthma (Trecos) | ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT06264674. Accessed August 15, 2024."},{"key":"3060_CR25","unstructured":"Workplace Environmental Exposure Level for 1,3,3,3-Tetrafluoropropylene, AIHA Guideline Foundation , 2011."},{"key":"3060_CR26","unstructured":"AstraZeneca progresses Ambition Zero Carbon programme with Honeywell partnership to develop next-generation respiratory inhalers. In: AstraZeneca website. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2022\/astrazeneca-progresses-ambition-zero-carbon-programme-with-honeywell-partnership-to-develop-next-generation-respiratory-inhalers.html#modal-historic-confirmation. Accessed July 5, 2024."},{"key":"3060_CR27","unstructured":"Study Details | Study to Assess Effect of HFO MDI Propellant on Mucociliary Clearance Vs. HFA MDI Propellant in Healthy Participants | ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05755932. Accessed August 14, 2024."},{"key":"3060_CR28","unstructured":"Hulse R, Boldt E, Decaire B, Smith G. A journey to net zero using solstice air. Respir Drug Del 2022: 97 \u2013 101."},{"key":"3060_CR29","unstructured":"United States Pharmacopeia. <661.1> Plastic Materials of Construction. \nhttps:\/\/www.uspnf.com\/. Accessed 10 Feb 2025."},{"key":"3060_CR30","unstructured":"United States Pharmacopeia. <661.2> Plastic Packaging Systems for Pharmaceutical Use. \nhttps:\/\/www.uspnf.com\/.\u00a0Accessed 10 Feb 2025."},{"key":"3060_CR31","unstructured":"United States Pharmacopeia. <1663> Assessment of Extractables Associated with Pharmaceutical Packaging\/Delivery Systems. \nhttps:\/\/www.uspnf.com\/.\u00a0Accessed 10 Feb 2025."},{"key":"3060_CR32","unstructured":"United States Pharmacopeia. <1664> Assessment of Drug Product Leachables Associated with Pharmaceutical Packaging\/Delivery Systems. \nhttps:\/\/www.uspnf.com\/.\u00a0Accessed 10 Feb 2025."},{"key":"3060_CR33","unstructured":"International Organization for Standardization (ISO). ISO 10993\u20131:2018 Biological evaluation of medical devicesPart 1: Evaluation and testing within a risk management process."},{"key":"3060_CR34","unstructured":"Koura, \u201cZephex\u00ae 152a Material Compatibility Sheet\u201d. https:\/\/www.kouraglobal.com\/applications\/medical-propellants\/zephex-152a\/. Accessed on July 5, 2024."},{"key":"3060_CR35","unstructured":"Corr S, Noakes T. Compatibility of P152a with pressurized metered dose inhaler device materials. Respir Drug Del 2018: 455\u2013458."},{"key":"3060_CR36","unstructured":"Deraime G, Ferrao J, Caneque Bueno L, Alix E, Williams G. Filling and dose performance of pMDIs with new low global warming potential propellants. Respir Drug Del 2023: 151\u20136."},{"key":"3060_CR37","unstructured":"Decaire B, Conviser S, Sarrailh S, Le Corre B, Baron C. Materials compatibility testing of Honeywell\u2019s new low global warming. https:\/\/advancedmaterials.honeywell.com\/content\/dam\/sustainability\/en\/documents\/document-lists\/technical\/poster-honeywell-propellants.pdf. Accessed on July 12, 2024."},{"key":"3060_CR38","unstructured":"Lachacz K, Taylor M, Morgan B, Archbell J, Craver J, Morris T, Carrigy NB, Ivatury S, Lechuga-Ballesteros D, Joshi V. Comparative aerosol performance of an HFA-134a based fixed-dose triple combination pMDI to one made with a near-zero carbon footprint propellant. Respir Drug Del 2023: 175\u201380."},{"key":"3060_CR39","unstructured":"Lechuga-Ballesteros D, Lachacz K, Joshi V, Riebe M. Quadruple combination in a pressurized metered dose inhaler with reduced environmental impact for the treatment of COPD. Respir Drug Del 2023: 181\u20134."},{"key":"3060_CR40","unstructured":"Lewis DA, Green JL, Turner R, Johnson RD, Lewis DI. HFA152a MDI Design: Matching the in-vitro performance of HFA227ea and HFA134a MDIs. Resp Drug Del 2023: 295\u20138."},{"key":"3060_CR41","unstructured":"Buttini F, Glieca S, Carretta G, Quarta E, Motta G, Carrara M, Colombo A. A roadmap for constructing a beclomethasone pMDI solution using HFA152a. Respir Drug Del 2023: 421\u20136."},{"key":"3060_CR42","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1080\/17425247.2023.2264184","volume":"20","author":"F Buttini","year":"2023","unstructured":"Buttini F, Glieca S, Sonvico F, Lewis DA. Metered dose inhalers in the transition to low GWP propellants: What We Know and What is Missing to Make it Happen. Expert Opin Drug Deliv. 2023;20:1131\u201343. https:\/\/doi.org\/10.1080\/17425247.2023.2264184.","journal-title":"Expert Opin Drug Deliv"},{"key":"3060_CR43","unstructured":"Brittain OM, Clay J, Riley D. An evaluation of solution and suspension pMDIs containing HFA152a and HFO1234ze using clinically relevant test methods. Respir Drug Del 2023: 227\u20134."},{"key":"3060_CR44","unstructured":"Mao L, Johnson S, Pant N, Murray J, Ellis D, Zechinati B, Carr J, Cruttenden V. Albuterol sulfate metered dose inhaler feasibility using an environment friendly propellant HFA152a and novel valves. Respir Drug Del 2023: 323\u20138."},{"key":"3060_CR45","unstructured":"Murray J, dge W, Moseley A. Anti-microbial properties of low-GWP pMDI propellant P-152a. Respir Drug Del 2023: 239\u20132."},{"key":"3060_CR46","unstructured":"Wang H, Ordoubadi M., Leal J, Minootan A, Lachacz K, Carrigy N, Lechuga-Ballesteros D, Vehring R. Droplet Characteristics of low global warming potential propellants at different ambient humidities. Respir Drug Del 2023: 383\u20136."},{"key":"3060_CR47","unstructured":"Jordan L, Johnson S, Chand R, Thurston G, Jones D, Webster V, Stanford S. Comparison of spray characteristics of P-134a and Low GWP P-152a pMDIs with and without ethanol. Respir Drug Del 2023: 311\u20136."},{"key":"3060_CR48","unstructured":"Honeywell Solstice\u00ae Air Technical Bulletin. 2022. https:\/\/advancedmaterials.honeywell.com\/content\/dam\/advancedmaterials\/en\/documents\/document-lists\/Solstice-Air-MDI-Technical-Bulletin.pdf. Accessed on July 15, 2024."},{"key":"3060_CR49","unstructured":"Le Corre B, Sarrailh S, Ferrao J. Investigation of leachables from pMDIs containing propellants HFA 134a, HFA 152a and HFO 1234ze. Respir Drug Del 2022: 209\u20132."},{"key":"3060_CR50","unstructured":"Faucard P, Fontaine I, Rives S, Le Corre B, Cannette C, Ferrao J. Leachables assessment from a new generation of pMDI using low global warming potential propellantsze. Respir Drug Del 2023: 163\u20138."}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-025-03060-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-025-03060-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-025-03060-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T13:18:15Z","timestamp":1748524695000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-025-03060-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":50,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["3060"],"URL":"https:\/\/doi.org\/10.1208\/s12249-025-03060-4","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,18]]},"assertion":[{"value":"28 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"65"}}